Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2002

01-09-2002 | Article

Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity

Authors: Julianna Pisch, Tibor Moskovitz, Olga Ésik, Peter Homel, Steven Keller

Published in: Pathology & Oncology Research | Issue 3/2002

Login to get access
Metadata
Title
Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity
Authors
Julianna Pisch
Tibor Moskovitz
Olga Ésik
Peter Homel
Steven Keller
Publication date
01-09-2002
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2002
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/BF03032389

Other articles of this Issue 3/2002

Pathology & Oncology Research 3/2002 Go to the issue

Article

Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas

In Memoriam

Outstanding cancerologist Leon M Shabad and his scientific activity (100th anniversary)

Article

Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages

Case Report

Primary neuroendocrine carcinoma of the mediastinum

Seminar

Molecular pathology of tumor metastasis

Case Report

Combined occurrence of prostate carcinoma and malacoplakia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits